Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31727311 | 0.90 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAKCNH2TP53 | |
| SCHEMBL5203786 | 0.88 | ALDH1A1 (0.60) | MAPTALDH1A1LMNAKCNH2TP53 | |
| SCHEMBL1247295 | 0.87 | MAPT (0.59) | MAPTALDH1A1LMNAKCNH2KMT2A | |
| SCHEMBL4460142 | 0.87 | MAPT (0.59) | MAPTALDH1A1LMNAKCNH2CCNT1 | |
| SCHEMBL6845367 | 0.86 | MAPT (0.56) | MAPTALDH1A1LMNAKCNH2CCNT1 | |
| SCHEMBL4178856 | 0.86 | MAPT (0.58) | MAPTALDH1A1LMNAKCNH2CCNT1 | |
| SCHEMBL29745194 | 0.86 | MAPT (0.58) | MAPTALDH1A1LMNAKCNH2CCNT1 | |
| SCHEMBL26351952 | 0.85 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAKCNH2CCNT1 | |
| SCHEMBL28773828 | 0.83 | MAPT (0.58) | MAPTALDH1A1LMNAKMT2AL3MBTL1 | |
| SCHEMBL29608605 | 0.83 | MAPT (0.58) | MAPTALDH1A1LMNAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | claimed |
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2025-06-03 | — | — | US | disclosed |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed Pharma S.A (PL) | 2024-08-29 | — | — | US | disclosed |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2024-05-14 | — | — | US | disclosed |
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | disclosed |
| US-20210276995-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2021-09-09 | — | — | US | disclosed |
| US-20210276995-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2021-09-09 | — | — | US | disclosed |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2021-06-15 | — | — | US | disclosed |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2021-06-15 | — | — | US | disclosed |
| CN-112041300-A | Indole and benzimidazole derivatives as dual 5-HT2A and5-HT 6receptor antagonists | 阿达梅德制药公司 | 2020-12-04 | — | — | CN | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7531542-B2 | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531542-B2 | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531542-B2 | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1904483-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20060264631-A1 | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | RECQL, AR, DHX35 | MAPT 3325/4885ALDH1A1 319/4885LMNA 606/4885 |
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | MAPT 338/4885ALDH1A1 505/4885LMNA 1535/4885 |
| US-20060264631-A1 | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor | GNRHR, GHRHR, LHCGR | MAPT 2825/4885ALDH1A1 4164/4885LMNA 4600/4885 |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR2C, HTR6 | MAPT 228/4885ALDH1A1 488/4885LMNA 1274/4885 |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | MAPT 338/4885ALDH1A1 505/4885LMNA 1535/4885 |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR6, HTR2C | MAPT 323/4885ALDH1A1 533/4885LMNA 1953/4885 |
| US-20210276995-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR2C, HTR6 | MAPT 228/4885ALDH1A1 488/4885LMNA 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.